What is the prognosis for patients with IDH2-mutant cancers?
The prognosis for patients with IDH2-mutant cancers varies depending on the type of cancer and the presence of other genetic and clinical factors. In general, IDH2 mutations are associated with a distinct clinical course, and the availability of targeted therapies has improved outcomes for some patients. However, more research is needed to fully understand the long-term impact of these mutations on prognosis.
